Dr. Mangla is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11100 Euclid Ave
Cleveland, OH 44106Phone+1 312-513-7437
Summary
- I am a medical oncologist with career interests in melanoma and soft-tissue sarcoma. I am a clinical researcher with a keen interest in bringing immunotherapy related trials. I am PI on several trials which are exploring the role of immunotherapy in both melanoma and sarcoma.
Education & Training
Cook County Health and Hospitals SystemFellowship, Hematology and Medical Oncology, 2015 - 2018- Cook County Health and Hospitals SystemResidency, Internal Medicine, 2012 - 2015
ArMed Forces Medical College PuneClass of 2007, MBBS
Certifications & Licensure
OH State Medical License 2017 - 2026
IL State Medical License 2015 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Highest Clinical Trial Accruals University Hospitals Seidman Cancer Center, 2023
- Certificate of Appreciation for Leading Accrual of Minority Research Participants in 2022 Case Western Reserve University School of Medicine, 2022
Clinical Trials
- A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Start of enrollment: 2015 Nov 23
- CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma Start of enrollment: 2018 Feb 15
- Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial Start of enrollment: 2018 Nov 15
- Join now to see all
Publications & Presentations
PubMed
- Inhibition of glutaminase elicits senolysis in therapy-induced senescent melanoma cells.Justin Kim, Bryce Brunetti, Ayanesh Kumar, Ankit Mangla, Kord Honda
Cell Death & Disease. 2024-12-18 - Corrigendum to 'Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States' [Clinical Lymphoma, Myeloma, and L...Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, Amin H Nassar, Elio Adib
Clinical Lymphoma, Myeloma & Leukemia. 2024-12-01 - Disparities in Receipt of Adjuvant Immunotherapy among Stage III Melanoma Patients.Kathleen M Mulligan, Hanna Kakish, Omkar Pawar, Fasih Ali Ahmed, Mohamedraed Elshami
American Journal of Clinical Oncology. 2024-11-01
Abstracts/Posters
- Net Clinical Benefit of Low Dose Rivaroxaban in Coronary Heart Disease: A Systematic Review and Meta-AnalysisAnkit Mangla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Systematic Review and Meta-Analysis of Cardio-Vascular Side Effects with Fostamatinib a Spleen Tyrosine Kinase InhibitorAnkit Mangla, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D DayJuly 25th, 2024- What Is Cardiac Angiosarcoma?November 29th, 2021
- Jimmy Buffett’s Death from Rare Skin Cancer Is a Reminder to Protect Skin from the SunSeptember 7th, 2023
- Join now to see all
Professional Memberships
- Member
- Member
- Society for immunotherapy in cancerMember
Other Languages
- Hindi
External Links
- Researchgate Profilehttps://www.researchgate.net/profile/Ankit_Mangla
- Google scholarhttps://scholar.google.com/citations?user=4Ag5MgUAAAAJ&hl=en
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
